Latest news
Loading news…
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.
ESBATech was acquired by Alcon in 2009 for $589M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- Schlieren, Zurich, Switzerland
Key People at ESBATech
Chief Financial Officer
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to ESBATech
Loading news…
FAQs about ESBATech
People who checked this page also checked these
Browse the full Acquirezy directory.